Lysyl Oxidase Propeptide Inhibits Prostate Cancer Cell Growth by Mechanisms That Target FGF-2-cell Binding and Signaling

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2009 Jul 15

PMID 19597471

Citations 46

Authors

A H Palamakumbura

S R Vora

M A Nugent

K H Kirsch

G E Sonenshein

P C Trackman

Affiliations

Soon will be listed here.

Abstract

Enhanced RAS signaling and decreased androgen dependence of prostate cancer cells accompany poor clinical outcomes. Elevated autocrine fibroblast growth factors 2 (FGF-2) signaling promotes prostate cancer cell growth and survival. Expression of lysyl oxidase (LOX) inhibits RAS transforming activity. LOX is secreted as 50 kDa pro-LOX protein and then undergoes extracellular proteolytic processing to form approximately 30 kDa LOX enzyme and approximately 18 kDa propeptide (LOX-PP). We have previously shown that LOX-PP inhibits breast cancer cell transformation and tumor formation, but mechanisms of action of LOX-PP have not been fully elucidated. Here we report that LOX expression is reduced in prostate cancer cell lines and that recombinant LOX-PP protein inhibits serum-stimulated DNA synthesis and MEK/ERK and PI3K/AKT pathways in DU 145 and PC-3 androgen-independent cell lines. In DU 145 cells, treatment with a pharmacologic FGF-receptor inhibitor or a neutralizing anti-FGFR1 antibody mimicked LOX-PP inhibition of serum-stimulated DNA synthesis. FGF-2-stimulated DNA synthesis, ERK1/2, AKT and FRS2alpha activation were found all to be inhibited by LOX-PP in DU 145 cells. LOX-PP reduced specific binding of FGF-2 to DU 145 cells, suggesting that LOX-PP targets FGF signaling at the receptor. Interestingly, PC-3 cells did not respond to FGF-2, consistent with previous reports. We conclude that LOX-PP inhibits proliferation of DU 145 cells by interfering with FGFR(s) binding and signaling, and that LOX-PP has other mechanisms of action in PC-3 cells.

Citing Articles

ITGB1/FERMT1 mechanoactivation enhances CD44 characteristic stemness in oral squamous cell carcinoma via ubiquitin-dependent CK1α degradation.

Li X, Zhao H, Jiang E, Liu P, Chen Y, Wang Y Oncogene. 2025; .

PMID: 40044983 DOI: 10.1038/s41388-025-03317-z.

The apoptotic and anti-proliferative effect of Lysyl oxidase propeptide in Y79 human retinoblastoma cells.

Nagaraj N, Natarajan S, Karunakaran C Mol Vis. 2024; 29:125-139.

PMID: 38222455 PMC: 10784223.

Mechanistic insight into lysyl oxidase in vascular remodeling and angiogenesis.

Wang Z, Guan Q, Zhou H, Mao X, Chen F Genes Dis. 2023; 10(3):771-785.

PMID: 37396555 PMC: 10308135. DOI: 10.1016/j.gendis.2022.05.011.

The Lysyl Oxidase G473A Polymorphism Exacerbates Oral Cancer Development in Humans and Mice.

Peymanfar Y, Mahjour F, Shrestha N, de la Cueva A, Chen Y, Huang S Int J Mol Sci. 2023; 24(11).

PMID: 37298359 PMC: 10254048. DOI: 10.3390/ijms24119407.

Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers.

Fuller A, Eisinger-Mathason T Cancers (Basel). 2022; 14(13).

PMID: 35804902 PMC: 9264969. DOI: 10.3390/cancers14133132.

References

Kenyon K, Contente S, Trackman P, Tang J, Kagan H, Friedman R . Lysyl oxidase and rrg messenger RNA. Science. 1991; 253(5021):802. DOI: 10.1126/science.1678898. View

Erler J, Bennewith K, Cox T, Lang G, Bird D, Koong A . Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2008; 15(1):35-44. PMC: 3050620. DOI: 10.1016/j.ccr.2008.11.012. View

Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, Papadimitriou E . Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J Biol Chem. 2006; 281(43):32217-26. DOI: 10.1074/jbc.M607104200. View

Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y . Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol. 2006; 72(4):427-36. DOI: 10.1016/j.bcp.2006.05.007. View

Contente S, Kenyon K, Rimoldi D, Friedman R . Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science. 1990; 249(4970):796-8. DOI: 10.1126/science.1697103. View

Ropiquet F, Giri D, Lamb D, Ittmann M . FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol. 1999; 162(2):595-9. View

Fannon M, Nugent M . Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem. 1996; 271(30):17949-56. DOI: 10.1074/jbc.271.30.17949. View

Kagan H, Li W . Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003; 88(4):660-72. DOI: 10.1002/jcb.10413. View

Payne S, Fogelgren B, Hess A, Seftor E, Wiley E, Fong S . Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 2005; 65(24):11429-36. DOI: 10.1158/0008-5472.CAN-05-1274. View

10.

Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh B . Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997; 276(5314):955-60. DOI: 10.1126/science.276.5314.955. View

11.

Nakamoto T, Chang C, Li A, Chodak G . Basic fibroblast growth factor in human prostate cancer cells. Cancer Res. 1992; 52(3):571-7. View

12.

Forsten-Williams K, Chua C, Nugent M . The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J Theor Biol. 2005; 233(4):483-99. DOI: 10.1016/j.jtbi.2004.10.020. View

13.

Giri D, Ropiquet F, Ittmann M . Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999; 5(5):1063-71. View

14.

Hamalainen E, Kemppainen R, Kuivaniemi H, Tromp G, Vaheri A, Pihlajaniemi T . Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem. 1995; 270(37):21590-3. DOI: 10.1074/jbc.270.37.21590. View

15.

Bansal R, Magge S, Winkler S . Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J Neurosci Res. 2003; 74(4):486-93. DOI: 10.1002/jnr.10773. View

16.

Ren C, Yang G, Timme T, Wheeler T, Thompson T . Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res. 1998; 58(6):1285-90. View

17.

Palamakumbura A, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein G . The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem. 2004; 279(39):40593-600. DOI: 10.1074/jbc.M406639200. View

18.

He Q, Wei Y, Tian L, Zhao X, Su J, Yang L . Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem. 2003; 278(24):21831-6. DOI: 10.1074/jbc.M300880200. View

19.

Zhao Y, Min C, Vora S, Trackman P, Sonenshein G, Kirsch K . The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem. 2008; 284(3):1385-93. PMC: 2615524. DOI: 10.1074/jbc.M802612200. View

20.

Blanckaert V, Venkateswaran S, Han I, Kim K, Griswold M, Schelling M . Partial characterization of endothelial FGF receptor functional domain by monoclonal antibody VBS-1. Hybrid Hybridomics. 2002; 21(3):153-9. DOI: 10.1089/153685902760173863. View